These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36564735)

  • 1. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ; Kim J; Kim S; Kim HJ
    BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS; Yoon WK; Choi EW
    Ir Vet J; 2023 Feb; 76(1):3. PubMed ID: 36755290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs.
    Ebisawa T; Ohta Y; Funayama M; Yamano S; Mizuno M; Mizuno T; Kasuya A; Sawada T; Lee J; Mizukoshi T; Uechi M
    Res Vet Sci; 2013 Jun; 94(3):717-21. PubMed ID: 23312500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A correlation between atrial natriuretic peptide, brain natriuretic peptide, and perioperative cardiac and renal functions in open heart surgery].
    Hata M; Masato O; Cho S; Narata M; Hata H; Inoue T; Sezai Y
    Nihon Kyobu Geka Gakkai Zasshi; 1997 Nov; 45(11):1797-802. PubMed ID: 9430955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure.
    Asano K; Masuda K; Okumura M; Kadosawa T; Fujinaga T
    J Vet Med Sci; 1999 May; 61(5):523-9. PubMed ID: 10379945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary-vein-to-pulmonary-artery ratio can be utilized to evaluate myxomatous mitral valve disease progression in dogs.
    Kim MS; Kim J; Seo MW; Park C
    Am J Vet Res; 2024 Jul; 85(7):. PubMed ID: 38663446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A; Bagardi M; Stranieri A; Zanaboni AM; Malchiodi D; Borromeo V; Brambilla PG; Locatelli C
    BMC Vet Res; 2021 Jan; 17(1):15. PubMed ID: 33413406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
    Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of atrial natriuretic peptide and cardiac troponin I concentrations for assessment of disease severity in dogs with naturally occurring mitral valve disease.
    Hori Y; Iguchi M; Hirakawa A; Kamiya Z; Yamano S; Ibaragi T; Isayama N; Yamashita Y; Iwasa N; Inaba H; Heishima Y; Yuki M
    J Am Vet Med Assoc; 2020 Feb; 256(3):340-348. PubMed ID: 31961274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S; Gordon SG; Fries R; Saunders AB; Sykes KT; Vitt J; Boutet B; Häggström J; Kadotani S; Stack J; Barnett BG
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.